Dolutegravir Impact on Residual Replication

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 28, 2015

Primary Completion Date

September 16, 2016

Study Completion Date

September 30, 2017

Conditions
HIV
Interventions
DRUG

dolutegravir

Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.

OTHER

Placebo

A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient

Trial Locations (2)

3010

Alfred Hospital, Prahran

3053

Melbourne Sexual Health Centre, Carlton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Alfred

OTHER

collaborator

ViiV Healthcare

INDUSTRY

lead

University of Melbourne

OTHER